Literature DB >> 9050098

Fibroblasts but not epithelial cells obtained from human nasal mucosa produce the chemokine RANTES.

S Maune1, I Berner, M Sticherling, R Kulke, J Bartels, J M Schröder.   

Abstract

RANTES is a chemokine that was already found in tissues obtained from nasal polyps of patients suffering from chronic polypous sinusitis. Its cellular origin is as yet unknown. The aim of this study was to investigate whether human nasal mucosa fibroblasts and epithelial cells are capable to produce RANTES. Fibroblasts and epithelial cells, obtained from healthy human nasal mucosa, were cultured. Expression of RANTES-mRNA and secretion of RANTES-protein in supernatants was investigated after stimulation with 50 ng/ml Tumour Necrosis Factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interferon-g (IFN-gamma), lipopolysaccharide (LPS), phorbolymyristate acetate (PMA) and serum-free medium (SFM) for 24 h. Cultivated nasal fibroblasts either expressed RANTES-mRNA or secreted RANTES protein upon TNF-alpha, IL-1 beta and IFN-gamma stimulation. The amounts of RANTES-protein production ranged from 23 ng/ml (PMA) to 198 ng/ml (TNF-alpha). Nasal epithelial cells expressed RANTES-mRNA only after stimulation with PMA. Secretion of significant amounts of RANTES protein were not detected in the supernatants from nasal epithelial cells. We conclude that nasal fibroblasts but not epithelial cells could be a cellular source of RANTES in nasal mucosa or in secretions of patients suffering from diseases, where eosinophilic tissue infiltration represents a characteristic histopathological feature.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9050098

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  8 in total

Review 1.  The Role of the Fibroblast in Inflammatory Upper Airway Conditions.

Authors:  Stephen L Ball; Derek A Mann; Janet A Wilson; Andrew J Fisher
Journal:  Am J Pathol       Date:  2015-12-10       Impact factor: 4.307

Review 2.  [Strategies of the nasal mucous membranes for defense against infection. Current knowledge of antimicrobial peptides].

Authors:  S Maune
Journal:  HNO       Date:  2005-05       Impact factor: 1.284

3.  Vitamin D deficiency is associated with increased human sinonasal fibroblast proliferation in chronic rhinosinusitis with nasal polyps.

Authors:  William W Carroll; Rodney J Schlosser; Brendan P O'Connell; Zachary M Soler; Jennifer K Mulligan
Journal:  Int Forum Allergy Rhinol       Date:  2016-01-11       Impact factor: 3.858

4.  Replenishment of RANTES mRNA expression in activated eosinophils from atopic asthmatics.

Authors:  J R Velazquez; P Lacy; R Moqbel
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

5.  Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors.

Authors:  A H Lee; J H Hong; Y S Seo
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

6.  Interleukin 5, IL6, IL12, IFN-gamma, RANTES and Fractalkine in human nasal polyps, turbinate mucosa and serum.

Authors:  Arild Danielsen; Turid Tynning; Karl A Brokstad; Jan Olofsson; Ake Davidsson
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-02-03       Impact factor: 2.503

7.  Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase.

Authors:  Russell W Jenkins; Christopher J Clarke; Daniel Canals; Ashley J Snider; Christopher R Gault; Linda Heffernan-Stroud; Bill X Wu; Fabio Simbari; Patrick Roddy; Kazuyuki Kitatani; Lina M Obeid; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

8.  Sphingosine kinase 1 regulates tumor necrosis factor-mediated RANTES induction through p38 mitogen-activated protein kinase but independently of nuclear factor κB activation.

Authors:  Mohamad M Adada; K Alexa Orr-Gandy; Ashley J Snider; Daniel Canals; Yusuf A Hannun; Lina M Obeid; Christopher J Clarke
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.